Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 726 results for innovative

  1. Innovative treatment of leakage and anastomotic insufficiency

    Topic prioritisation

  2. NICE encourages further research into the use of innovative technologies for the management of severe acute respiratory failure, and may review this guidance on publication of further evidence.

    IPG391/1 Question NICE encourages further research into the use of innovative technologies for the management of severe acute...

  3. Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) (TA1032)

    NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is because Johnson & Johnson Innovative Medicine did not provide an evidence submission.

    Sections for TA1032

  4. Health Technology Assessment Innovation Laboratory (HTA Lab)

    NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.

  5. One-piece closed bags for colostomies: late-stage assessment (HTG754)

    Late stage assessment (LSA) guidance on one-piece closed bags for colostomies

  6. Register your organisation as a stakeholder

    Our stakeholders are involved in the development of NICE guidance and quality standards to ensure that the recommendations are relevant, practical, and meet the needs of those affected by the health or social care issues addressed.

  7. Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.

  8. Obeticholic acid for treating primary biliary cholangitis (TA443)

    Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.

  9. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

    Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

  10. Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

    Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.

  11. Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)

    Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.

  12. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.

  13. Ustekinumab for treating active psoriatic arthritis (TA340)

    Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.

  14. Leukomed Sorbact for preventing surgical site infection (HTG567)

    Evidence-based recommendations on Leukomed Sorbact for preventing surgical site infection after caesarean section or vascular surgery.